Kalaris Therapeutics (Nasdaq: KLRS) reported positive data from expanded cohorts in its Phase 1a single ascending dose trial of TH103 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE